$IDYA News

Last published 1w ago

1w agoIDYAIDEAYA Biosciences, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoIDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireSOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted
2w agoIDYAIDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine CarcinomasPR Newswire17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5% (55/101) cORR in 2L +
3w agoIDYAIDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal MelanomaPR NewswireOptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective of HLA-A*02:01 allele status or
1mo agoIDYAIDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and DevelopmentPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
1mo agoIDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
1mo agoIDYAMorgan Stanley 24th Annual Global Healthcare Conference - IDEAYA BIOSCIENCES INCEarnings Call TranscriptsGood morning. Thank you for coming this morning to the Morgan Stanley Healthcare Conference. My name is Ruck Byun. I'm the head of West Coast Healthcare Investment Banking at Morgan Stanley. I have the pleasure of hostin
2mo agoIDYAIDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal MelanomaPR NewswireIDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Servier, an independent international pharmaceutical...
2mo agoIDYAIDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor ConferencesPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
2mo agoIDYAIDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung CancerPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
2mo agoIDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
2mo agoIDYAIDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic CancerPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
3mo agoIDYAIDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business UpdatePR NewswireIDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of...
3mo agoIDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
3mo agoIDYAIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung CancersPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that initiation of Part 2 monotherapy...
3mo agoIDYAIDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical ProgramsPR NewswireIDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced three abstract presentations at the 2026...
4mo agoIDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
4mo agoIDYAIDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of DirectorsPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that its Board of Directors has elected...
4mo agoIDYAIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung CancersPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in...
5mo agoIDYAIDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesPR NewswireIDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common stock at a...
5mo agoIDYAIDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded WarrantsPR NewswireIDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA ...
5mo agoIDYAIDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsPR NewswireIDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock and, in...
5mo agoIDYAJeffries Global Healthcare Conference in New York - IDEAYA BIOSCIENCES INCEarnings Call TranscriptsI really appreciate it. Good morning, everyone. My name is Akash Jowari. I head our pharma and biotech research efforts here at Jefferies. This is our New York City healthcare conference, which I always enjoy. And it's g
5mo agoIDYAIDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic CancerPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
5mo agoIDYAIDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCOPR NewswireIDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Servier, an independent international pharmaceutical...
5mo agoIDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
5mo agoIDYATD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHAIDEAYA BIOSCIENCES INCEarnings Call TranscriptsGreat. Good morning, everyone. Hope everyone had a great long weekend. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen. Thank you very much for attending TD Cowens 7th Annual Oncology Innovation Summit. For our
5mo agoIDYAIDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare ConferencePR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
5mo agoGTBP SMMT IDYA GSK+1B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters ClinicPR NewswireUSA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could ...
6mo agoGTBP IDYA RADX SMMTA Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in OncologyGlobeNewswireIssued on behalf of GT Biopharma, Inc. From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has become one of the most actively pursued antigens in solid tumor oncology — and a new natural killer cell
6mo agoIDYA2026 GLOBAL HEALTHCARE CONFERENCEIDEAYA BIOSCIENCES INCEarnings Call Transcriptsback to the Bank of America Healthcare Conference. I'm Tezeen Ahmad. I'm one of the senior biotech analysts here at the bank. Our next presenting company is Ideya Biosciences and sitting up here on stage with me are two
6mo agoIDYAIDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdatePR NewswireIDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results...
6mo agoIDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
6mo agoIDYAIDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) ProgramPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced that the U.S. Food and Drug Administration (FDA) has...
6mo agoIDYAIDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal MelanomaPR NewswireIDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking...
7mo agoIDYAIDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal MelanomaPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, and Servier, an independent international pharmaceutical group...
7mo agoIDYAIDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026PR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pre-market...
7mo agoIDYAIDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung CancerPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in...
7mo agoIDYAIDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and MelanomaPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
7mo agoIDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
7mo agoIDYAIDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 TrialPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
7mo agoIDYAIDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline ProgramsPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for three poster ...
8mo agoIDYAIDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline UpdatePR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in...
8mo agoIDYABiocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034Business WireIDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA's PARG inhibitor
8mo agoIDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
8mo agoIDYAIDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADCPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in...
8mo agoIDYAIDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development OfficerPR NewswireIDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced the appointment of Dr. Theodora (Theo) Ross...
8mo agoIDYAIDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdatePR NewswireIDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results...
9mo agoIDYAIDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations EventsPR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...
9mo agoIDYAIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireIDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...